Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

Status Completed

Clinical Trial Summary

Clinical Trial Description

The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.

Secondary objectives include:

- To compare response rate of patients in both treatment arms

- To compare overall survival of patients in both treatment arms

- To compare toxicity in both treatment arms

- To determine whether the survival benefit from suramin is associated with reduced M-phase entry in peripheral blood lymphocytes ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01671332
Study type	Interventional
Source	University of Wisconsin, Madison
Contact
Status	Completed
Phase	Phase 2
Start date	June 2012
Completion date	June 16, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02135211` - Healthy Directions After Lung Surgery Pilot	N/A
Completed	`NCT00191230` - Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer	Phase 2
Withdrawn	`NCT01004419` - Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer	Phase 1
Terminated	`NCT00905801` - Computed Tomography (CT) Perfusion Imaging of Lung Cancer	N/A
Recruiting	`NCT00184964` - Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis	N/A
Completed	`NCT00191256` - Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer	Phase 2
Completed	`NCT00954278` - Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer	Phase 1
Terminated	`NCT01282151` - TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer	Phase 3
Terminated	`NCT01088906` - Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC	Phase 2
Completed	`NCT00553254` - Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer	Phase 2
Completed	`NCT01469000` - A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)	Phase 2
Withdrawn	`NCT00934076` - Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer	Phase 1
Completed	`NCT00798720` - Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer	Phase 2
Terminated	`NCT01891669` - A Study Of PF-06263507 In Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00160069` - Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer	Phase 2
Completed	`NCT00548093` - PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib	Phase 2